{"product_id":"selank-5mg","title":"Selank 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/SELANK_5MG_GLOSS.png?v=1779037208\" alt=\"\"\u003eSelank 5mg is a synthetic heptapeptide compound designed for research and laboratory use. This high-purity formulation delivers 5 milligrams of Selank, a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin, suitable for scientific investigation and experimental applications exploring cognitive function, mood regulation, and immune response modulation. Each vial is manufactured to exacting standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying peptide interactions with neurotransmitter systems, anxiolytic pathways, and immunological responses. Store in a cool, dry place away from direct light. For research purposes only.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Selank (synthetic tuftsin-derived heptapeptide) Concentration: 5mg per vial Purity: Research-grade Format: Lyophilized powder Storage: Cool, dry environment, 2–8°C (refrigerated) Shelf Life: Refer to batch documentation for expiration details Intended Use: Laboratory and research applications only Quality Standard: Manufactured to pharmaceutical-grade consistency protocols Suitable for qualified researchers, academic institutions, and licensed laboratories conducting cognitive, immunological, and neuropeptide research.\u003c\/p\u003e\n\u003cp\u003eMolecular Formula: C₃₄H₆₁N₁₅O₁₂ Molecular Weight: 821.97 g\/mol CAS Number: 61352-05-6 Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro Sequence Classification: Synthetic linear heptapeptide derived from the C-terminal tetrapeptide sequence of tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro extension for enhanced stability and CNS penetration Mechanism: Modulates GABA-A receptor activity and influences BDNF expression, serotonin, and dopamine neurotransmitter systems; studied for anxiolytic, nootropic, and immunomodulatory properties without sedative effects Purity Analysis: ≥95% by HPLC This molecular data supports advanced research into neuropeptide pharmacology, anxiety pathway modulation, and immune system regulation studies.\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store the sealed vial at 2–8°C (refrigerated) or at room temperature (15–25°C) in a cool, dry place away from direct sunlight and heat sources. Keep in original packaging to protect from light exposure. Unopened vials maintain stability for the duration specified in batch documentation when stored under these conditions. Storage After Reconstitution: Once reconstituted with bacteriostatic water or sterile saline, store the solution at 2–8°C (refrigerated). Reconstituted solution should be used within the timeframe indicated in your batch documentation. Avoid repeated freeze-thaw cycles, which may compromise peptide integrity. Keep the vial upright and away from direct light during storage. General Handling: Maintain sterile technique during reconstitution. Do not expose to extreme temperatures or prolonged room temperature conditions after mixing. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank: Design, Synthesis, and Anxiolytic Profile\u003c\/strong\u003e\u003cbr\u003eSemenova TP, et al. (2010). \u003cem\u003eSelank and short peptides of the tuftsin family in the regulation of adaptive behaviour in rats under conditions of emotional stress.\u003c\/em\u003e Peptides, 31(5), 921–926. \u003ca href=\"https:\/\/doi.org\/10.1016\/j.peptides.2010.02.006\"\u003ehttps:\/\/doi.org\/10.1016\/j.peptides.2010.02.006\u003c\/a\u003e\u003cbr\u003eCharacterises Selank’s anxiolytic and anti-stress activity in rodent models of emotional stress, demonstrating dose-dependent attenuation of anxiety-related behaviour without sedation — establishing the foundational pharmacological profile for Selank research in anxiety pathway modulation and stress neurobiology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and BDNF Expression in the Rat Brain\u003c\/strong\u003e\u003cbr\u003eInozemtseva LS, et al. (2008). \u003cem\u003eIntranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus.\u003c\/em\u003e Doklady Biological Sciences, 421(1), 241–243. \u003ca href=\"https:\/\/doi.org\/10.1134\/S0012496608040066\"\u003ehttps:\/\/doi.org\/10.1134\/S0012496608040066\u003c\/a\u003e\u003cbr\u003eDemonstrates that intranasal Selank administration significantly upregulates BDNF mRNA expression in the rat hippocampus, providing the key neurotrophic mechanism of action for researchers studying Selank in neuroplasticity, memory consolidation, and neuroprotective peptide models.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and GABAergic Neurotransmission: Anxiolytic Mechanism\u003c\/strong\u003e\u003cbr\u003eZozulya AA, et al. (2001). \u003cem\u003eThe influence of Selank on anxiety-related behaviour in rats: interaction with the GABAergic system.\u003c\/em\u003e Bulletin of Experimental Biology and Medicine, 131(5), 464–466. \u003ca href=\"https:\/\/doi.org\/10.1023\/A:1017928116025\"\u003ehttps:\/\/doi.org\/10.1023\/A:1017928116025\u003c\/a\u003e\u003cbr\u003eDemonstrates Selank’s modulation of GABA-A receptor activity and its interaction with benzodiazepine binding sites, establishing the GABAergic mechanism underlying its anxiolytic effects without sedative or amnesic side effects — providing mechanistic context for researchers studying peptide-based anxiolytic compounds.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and Immunomodulatory Activity: Tuftsin-Derived Effects\u003c\/strong\u003e\u003cbr\u003eUchakina ON, et al. (2008). \u003cem\u003eImmunomodulatory effects of Selank in patients with anxiety-asthenic disorders.\u003c\/em\u003e Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 108(5), 71–75. PMID: 18577961\u003cbr\u003eClinical investigation of Selank’s immunomodulatory effects in patients with anxiety disorders, demonstrating normalisation of cytokine profiles (IL-6, TNF-α) and T-cell activity — providing translational evidence for Selank’s dual neuropeptide and immunoregulatory research applications derived from its tuftsin structural origin.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSelank and Enkephalin Metabolism: Opioid System Interaction\u003c\/strong\u003e\u003cbr\u003eKost NV, et al. (2001). \u003cem\u003eSelank inhibits enkephalin-degrading enzymes in human serum.\u003c\/em\u003e Bulletin of Experimental Biology and Medicine, 131(4), 362–364. \u003ca href=\"https:\/\/doi.org\/10.1023\/A:1017945809338\"\u003ehttps:\/\/doi.org\/10.1023\/A:1017945809338\u003c\/a\u003e\u003cbr\u003eDemonstrates that Selank inhibits enkephalin-degrading enzymes in human serum, prolonging endogenous opioid peptide activity and providing a novel mechanistic pathway for its anxiolytic and mood-modulating effects — expanding the research framework for Selank into endogenous opioid system regulation and neuropeptide stability studies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248662470999,"sku":"SK5","price":14.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/SELANK_5MG_GLOSS.png?v=1779037208","url":"https:\/\/www.mutantpeptides.com\/products\/selank-5mg","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}